Skip to main content

Coronavirus (COVID-19) Updates: Visitation Policies (New! 11.25.20) | How We're Keeping You Safe | Latest COVID Information

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
URMC / Research / Clinical Trials / Study Details

Amyloidosis: S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

Research Question:
What are the good and bad effects of the study drug called isatuximab?

Basic Study Information

All participants will receive the same study drug. If you decide to participate, you will receive up to 24 cycles (1 cycles = 28 days) of the study drug, isatuximab, as an outpatient (meaning you will not be admitted to the hospital to receive study drug. During the first cycle (or 28 days), you will receive isatuximab on Day 1, 8, 15 and 22 by intravenous (IV) infusion (into your vein). For all other cycles (Cycle 2, up to Cycle 24), you will receive isatuximab on Days 1 and 15.

Location: Cancer Center
Study Web URL:
Study Reference #: CMMY18034

Lead Researcher (Principal Investigator)

Lead Researcher:  Frank Passero

Study Contact Information

Study Coordinator: Andrew Bui
Phone: (585) 276-4405

Additional Study Details

Learn More About These Conditions

More information about Amyloidosis

Return to Search